Global Viscosupplementation Market Insights Forecasts to 2033

• The Global Viscosupplementation Market Size was Valued at USD 4.20 Billion in 2023
• The Market Size is Growing at a CAGR of 8.10% from 2023 to 2033
• The Worldwide Viscosupplementation Market Size is Expected to Reach USD 9.15 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Viscosupplementation Market Size is Anticipated to Exceed USD 9.15 Billion by 2033, Growing at a CAGR of 8.10% from 2023 to 2033.

Market Overview

Viscosupplementation is a medical treatment in which a gel-like substance called hyaluronic acid is injected into a joint, typically the knee, to help primarily alleviate joint pain, most commonly associated with osteoarthritis. Viscosupplementation treatment is often used to relieve pain and improve mobility in patients with osteoarthritis, a condition characterized by the degeneration of joint cartilage and the underlying bone. Viscosupplementation consists of hyaluronic acid (HA), a substance naturally found in the synovial fluid of joints, which acts as a lubricant and shock absorber. In osteoarthritis, the concentration and quality of hyaluronic acid in the synovial fluid decrease, leading to increased friction, inflammation, and pain in the affected joints. Viscosupplementation provides numerous benefits, including reduced friction, improved synovial fluid cushioning, relief of severe pain, and increased joint range of motion. Viscosupplementation improves the rheological properties of synovial fluid, providing mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation has become widely used to treat knee, hip, and hand osteoarthritis, with solutions available in intermediate, low, and high molecular weights. The viscosupplementation entails injecting hyaluronic acid or derivative solutions into the knee joint space in an attempt to restore normal joint fluid viscosity levels. By augmenting the natural joint fluid lubricant, viscosupplementation products attempt to alleviate pain and enhance mobility for osteoarthritis sufferers. In November 2022, Washington State Health Care published a report that osteoarthritis (OA) is one of the most frequent disabilities in the United States, affecting around 32.5 million Americans. This figure is expected to rise in the future years, reaching as high as 29.5% of US people over the age of 45 by 2032.

Report Coverage

This research report categorizes the market for the global viscosupplementation market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global viscosupplementation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global viscosupplementation market.

Driving Factors

The global viscosupplementation market is driven by several key factors. The aging population and rising incidence of osteoarthritis due to factors like obesity and sedentary lifestyles significantly boost demand for viscosupplementation. Increasing awareness and acceptance of viscosupplementation as a minimally invasive treatment, along with technological advancements such as single-injection hyaluronic acid treatments, further propel market growth. As a minimally invasive alternative to surgery, viscosupplementation offers significant pain relief and improved mobility with a favorable safety profile, making it a preferred option for many patients. Improved healthcare expenditure in developing regions and favorable regulatory approvals enhance market accessibility. The growing prevalence of sports-related injuries, positive patient outcomes, and strategic collaborations among market players also contribute to the expansion of the viscosupplementation market. Overall, these factors collectively stimulate the demand and adoption of viscosupplementation treatments worldwide.

Restraining Factors

The market for viscosupplementation faces various barriers to expansion, including high production costs due to advanced technology and premium raw ingredients, strict regulatory obstacles, and low consumer awareness. Regulatory hurdles, including varying standards across regions, hinder new product approvals. Supply chain and distribution issues affect market dynamics, as do demands for scientific proof of health claims. Furthermore, the market has seen slower uptake in developing countries because of reduced awareness and greater treatment costs. Patients might also be unwilling to undergo repeated intraarticular injections.

Market Segmentation

The global viscosupplementation market share is classified into dosage, arthritis type, and end-user.

• The three-injection segment dominates the market with the largest market share through the forecast period.

Based on the dosage, the global viscosupplementation market is categorized into single-injection, three-injection, and five-injection. Among these, the three-injection segment dominates the market with the largest market share through the forecast period. The most commonly utilized method for treating osteoarthritis is the three-injection procedure, due to its effectiveness. Medical practitioners often favor three injections to help avoid total knee replacement surgery in cases of osteoarthritis. Furthermore, the availability of numerous three-injection segments in the market helps to increase market share. Furthermore, several clinical trials have been approved and demonstrated favorable outcomes for their three-injection techniques to treat osteoarthritis.

• The osteoarthritis segment is anticipated to hold the highest market share through the forecast period.

On the basis of arthritis type, the global viscosupplementation market is classified into osteoarthritis and rheumatoid arthritis. Among these, the osteoarthritis segment is anticipated to hold the highest market share through the forecast period. The large number of eligible patients makes it the dominant market segment. Additionally, the degenerative nature of osteoarthritis often limits the effectiveness of alternative treatments like medication management alone. Viscosupplementation offers a minimally invasive solution preferred by both patients and providers over joint replacement in the earlier stages of the disease. The aging global population increases the prevalence of osteoarthritis. Obesity, previous joint traumas, and heredity all increase the risk of prevalence of this condition.

• The hospitals segment accounted for the largest revenue share through the forecast period.

Based on the end-user, the global viscosupplementation market is divided into hospitals, specialty clinics, home healthcare, ambulatory surgical centers, and others. Among these, the hospitals segment accounted for the largest revenue share through the forecast period. This is due to higher patient volumes, advanced medical infrastructure, specialized healthcare professionals, better insurance coverage, and comprehensive care available in hospital settings. Hospitals also have advanced imaging technology that allows for reliable assessment and tracking of therapy progress.

Regional Segment Analysis of the Global Viscosupplementation Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global viscosupplementation market over the predicted timeframe.

North America is anticipated to hold the largest share of the global viscosupplementation market over the predicted timeframe. North America is estimated to hold the highest market share due to several factors including high prevalence of osteoarthritis, advanced healthcare infrastructure, high awareness and acceptance of treatments, favorable reimbursement policies, strong research and development activities, a supportive regulatory environment, and higher disposable incomes. These elements collectively drive the demand and adoption of viscosupplementation treatments in the region.

Asia Pacific is expected to grow at the fastest CAGR growth of the global viscosupplementation market during the forecast period. Countries such as China, India, Japan, and South Korea are seeing a significant increase in knee osteoarthritis cases, owing to an aging population and the rising frequency of lifestyle diseases. Several key driving factors of this growth include the increasing prevalence of osteoarthritis, growing awareness and acceptance of viscosupplementation, advancements in healthcare infrastructure, rising disposable incomes, supportive government initiatives, and increasing healthcare expenditure.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global viscosupplementation market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sanofi
• Hoffmann-La Roche
• Bioventus
• Zimmer Biomet
• Anika Therapeutics Inc.
• Seikagaku Corporation
• Mylan N.V.
• Aptissen
• Ferring Pharmaceuticals
• OrthogenRx
• Johnson and Johnson
• Ono Pharmaceuticals
• Lifecore Biomedical
• F.Hoffmann
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2022, Juniper Biologics licensed TissueGene-C low dose (TG-C LD), a non-surgical treatment for knee osteoarthritis, to Kolon Life Sciences for development and commercialization. According to the licensing agreement, Juniper will develop and commercialize gene therapy to medical professionals and hospitals in Asia-Pacific, the Middle East, and Africa.

• In March 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation launched JOYCLU 30mg intra-articular injection, a therapeutic agent for improving joint function. Seikagaku received manufacturing and marketing permission for this product in Japan.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global viscosupplementation market based on the below-mentioned segments: 

Global Viscosupplementation Market, By Dosage

• Single-Injection
• Three-Injection
• Five-Injection

Global Viscosupplementation Market, By Arthritis Type

• Osteoarthritis
• Rheumatoid Arthritis

Global Viscosupplementation Market, By End User

• Hospitals

• Specialty Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Others

Global Viscosupplementation Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa